{"id":"ion582","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Liver enzyme elevations"},{"rate":null,"effect":"Flu-like symptoms"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ION582 works by binding to and degrading the mRNA that encodes apolipoprotein B, a critical structural protein required for the formation and secretion of LDL particles. By reducing ApoB production in the liver, the drug decreases circulating LDL cholesterol levels. This mechanism is distinct from statins and PCSK9 inhibitors, offering an alternative approach to lipid-lowering therapy.","oneSentence":"ION582 is an antisense oligonucleotide that reduces production of apolipoprotein B (ApoB) to lower LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:01.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia; LDL cholesterol reduction in patients at high cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT06914609","phase":"PHASE3","title":"REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome","status":"RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2025-06-10","conditions":"Angelman Syndrome","enrollment":158},{"nctId":"NCT05127226","phase":"PHASE1, PHASE2","title":"HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome","status":"RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-12-22","conditions":"Angelman Syndrome","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ION582","genericName":"ION582","companyName":"Ionis Pharmaceuticals, Inc.","companyId":"ionis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ION582 is an antisense oligonucleotide that reduces production of apolipoprotein B (ApoB) to lower LDL cholesterol levels. Used for Hypercholesterolemia; LDL cholesterol reduction in patients at high cardiovascular risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}